SIETES :: 93212 citas

Resultados de la búsqueda por IMIPENEM-CILASTATINA REFINAR BÚSQUEDA

1.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: A pharmacovigilance study of the FDA adverse event reporting system. International Journal of Medical Sciences 2019;16:julio. [Ref.ID 103207]

2.

Anónimo. Infection d'une plaie du pied chez un patient diabétique. Prescrire 2014;34:674-80. [Ref.ID 98093]

3.

Anónimo. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia. U.S. Food and Drug Administration 2014:6 de marzo. [Ref.ID 97188]

4.

Anónimo. Doripenem. Higher mortality rate and a lower clinical cure rate observed during a comparative clinical trial. Canada. WHO Pharmaceuticals Newsletter 2012;2:abril. [Ref.ID 92614]

5.

Anónimo. Méropénem dans diverses infections de plus. Toujours pas d'avantage clinique. Prescrire 2010;30:808. [Ref.ID 89591]

6.

Esteban Jiménez Ó, Navarro Pemán C, Baile Estopañán G, González Rubio F. Crisis epilépticas como reacción adversa a medicamentos. Med Clin (Barc) 2009;132:328-9. [Ref.ID 85490]

7.

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J, for the Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34. [Ref.ID 84961]

8.

Anónimo. What role for tigecycline in infections?. Drug Ther Bull 2008;46:62-4. [Ref.ID 83796]

9.

Anónimo. Vioxx charges mean fourth-quarter loss for Merck & Co. Scrip 2008;3333:12. [Ref.ID 82134]

10.

Anónimo. Hoquet d'origine médicamenteuse. Prescrire 2008;28:24. [Ref.ID 81927]

11.

Linden P. Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. Drug Saf 2007;30:657-68. [Ref.ID 80966]

12.

Itani KMF, Abramson MA. Antibiotic prophylaxis in colorectal surgery. The authors reply. N Engl J Med 2007;356:1685. [Ref.ID 79845]

13.

Spievack AR. Antibiotic prophylaxis in colorectal surgery. N Engl J Med 2007;356:1685. [Ref.ID 79844]

14.

Moine P, Asehnoune K. Antibiotic prophylaxis in colorectal surgery. N Engl J Med 2007;356:1684. [Ref.ID 79843]

15.

Anónimo. Vioxx and restructuring costs hit Merck & Co's fourth quarter. Scrip 2007;3231:10. [Ref.ID 79162]

16.

Sexton DJ. Carbapenems for surgical prophylaxis?. N Engl J Med 2006;355:2693-5. [Ref.ID 78760]

17.

Itani KMF, Wilson SE, Awad SS, Jensen EH, Finn TS, Abramson MA. Ertapenem versus cefotetan prophylaxis in elective colorectal surgery. N Engl J Med 2006;355:2640-51. [Ref.ID 78759]

18.

Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006;367:633-4. [Ref.ID 76242]

19.

Anónimo. Merck & Co beats expectations despite new Vioxx reserve. Scrip 2006;3128:8. [Ref.ID 76088]

20.

Anónimo. Merck & Co adds $604 million to Vioxx litigation reserve. Scrip 2005;3024:7. [Ref.ID 72637]